Various studies on JAK2-mediated signaling and leukemogenesis have also utilized several JAK2-V617F-positive cell lines derived from patients with post-MPN sAML [5], including the PVTL-1 cell line we previously established from a patient with AML evolving from PV [6]. This evidence concerns the gene JAK2 and myeloproliferative disorder.